Comparative cardiovascular risks of canagliflozin and selective SGLT2 inhibitors in type 2 diabetes

AimsDual inhibition of sodium-glucose cotransporter (SGLT) 1 and 2 with canagliflozin may offer additional metabolic effects beyond selective SGLT2 inhibition; however, its comparative cardiovascular associations remain uncertain. This study compared the risks of major adverse cardiovascular events...

Full description

Bibliographic Details

Published in:	Frontiers in Pharmacology
Main Authors:	Edy Kornelius, Shih-Chang Lo, Yi-Sun Yang, Yu-Hsun Wang, Chien-Ning Huang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-10-01
Subjects:	SGLT1 SGLT2 MACE mortality diabetes
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2025.1686851/full